ATR and non-small cell lung carcinoma: Given the pivotal role of DDR in resistance mechanisms, targeting DDR components, such as ATR, DNA-PK, and PARP inhibitors, presents a promising approach to increasing chemotherapy sensitivity and enhancing therapeutic outcomes in NSCLC.